This document summarizes key information about double hit lymphomas and other molecularly defined large B-cell lymphomas. It discusses how approximately 40% of B-cell lymphomas involve chromosomal translocations involving oncogenes like MYC and BCL2. Double hit lymphomas specifically involve recurrent breakpoints activating both MYC and another oncogene like BCL2. These tumors have a germinal center B-cell phenotype and poor response to standard R-CHOP chemotherapy, with median survival usually less than 1 year. More intensive chemotherapy regimens like dose-adjusted EPOCH show promise for improving outcomes in double hit lymphoma and other MYC-rearranged large B-cell lymphomas.
This is a concise presentation on the pathology of endometrial cancer based on the latest WHO female genital tumors latest edition, 5th edition
prepared on April 2022
This is a concise presentation on the pathology of endometrial cancer based on the latest WHO female genital tumors latest edition, 5th edition
prepared on April 2022
diffuse large B cell lymphoma recent molecular classification
molecular classification and their time frame with references
Recent advantages of DLBCL and thier implication in therapy
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
JMeter webinar - integration with InfluxDB and GrafanaRTTS
Watch this recorded webinar about real-time monitoring of application performance. See how to integrate Apache JMeter, the open-source leader in performance testing, with InfluxDB, the open-source time-series database, and Grafana, the open-source analytics and visualization application.
In this webinar, we will review the benefits of leveraging InfluxDB and Grafana when executing load tests and demonstrate how these tools are used to visualize performance metrics.
Length: 30 minutes
Session Overview
-------------------------------------------
During this webinar, we will cover the following topics while demonstrating the integrations of JMeter, InfluxDB and Grafana:
- What out-of-the-box solutions are available for real-time monitoring JMeter tests?
- What are the benefits of integrating InfluxDB and Grafana into the load testing stack?
- Which features are provided by Grafana?
- Demonstration of InfluxDB and Grafana using a practice web application
To view the webinar recording, go to:
https://www.rttsweb.com/jmeter-integration-webinar
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...DanBrown980551
Do you want to learn how to model and simulate an electrical network from scratch in under an hour?
Then welcome to this PowSyBl workshop, hosted by Rte, the French Transmission System Operator (TSO)!
During the webinar, you will discover the PowSyBl ecosystem as well as handle and study an electrical network through an interactive Python notebook.
PowSyBl is an open source project hosted by LF Energy, which offers a comprehensive set of features for electrical grid modelling and simulation. Among other advanced features, PowSyBl provides:
- A fully editable and extendable library for grid component modelling;
- Visualization tools to display your network;
- Grid simulation tools, such as power flows, security analyses (with or without remedial actions) and sensitivity analyses;
The framework is mostly written in Java, with a Python binding so that Python developers can access PowSyBl functionalities as well.
What you will learn during the webinar:
- For beginners: discover PowSyBl's functionalities through a quick general presentation and the notebook, without needing any expert coding skills;
- For advanced developers: master the skills to efficiently apply PowSyBl functionalities to your real-world scenarios.
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Accelerate your Kubernetes clusters with Varnish CachingThijs Feryn
A presentation about the usage and availability of Varnish on Kubernetes. This talk explores the capabilities of Varnish caching and shows how to use the Varnish Helm chart to deploy it to Kubernetes.
This presentation was delivered at K8SUG Singapore. See https://feryn.eu/presentations/accelerate-your-kubernetes-clusters-with-varnish-caching-k8sug-singapore-28-2024 for more details.
Accelerate your Kubernetes clusters with Varnish Caching
DOUBLE HIT AND OTHER MOLECULARLY DEFINED LARGE CELL LYMPHOMAS
1. DOUBLE HIT AND OTHER MOLECULARLY
DEFINED LARGE CELL LYMPHOMAS
Morton Coleman, M.D.
Director, Center for Lymphoma and Myeloma
New York-Presbyterian Hospital Weill Cornell Medical Center
Clinical Professor of Medicine
Weill Cornell Medical College
Chairman, Medical Affiliates Board
Lymphoma Research Foundation
2. Chromosomal translocations in
lymphoma and MYC
• 40% of B cell lymphomas have recurrent
reciprocal translocations
– May be subtype specific
– Often oncogene plus Ig loci enhancer
• t(8;14)(q24;q32) – lymphoma initiating in BL
• MYC breakpoints may be secondary events
in other lymphomas
• At diagnosis or at progression
• In MYC+ DLBCL and DH lymphoma, often
non Ig-MYC breakpoints
4. Chromosomal breakpoints in DLBCL
Aukema et al, Blood 2011
Study N
MYC+
total %
MYC+
SH %
BCL2/
MYC+ DH
%
BCL6/
MYC+
DH %
BCL2/
BCL6/
MYC+ TH
%
All DH and
TH %
Barrans 2010 245 14% 2% 8% 1% 3% 12%
Obermann
2009
220 4% 3% 0 0 0 1%
Yoon 2008 137 7% 7% 1% 1% 1% 3%
Tibiletti 2009 74 16% 4% 7% 7% 1% 12%
Copie-
Bergman
2009
68 3% 3% 0 0 0 0
Van Imhoff
2006
58 15% 8% 5% 2% 0 7%
Savage 2009 135 9% 7% 2% NA NA NA
Klapper 2008 117 8% NA NA NA NA NA
5. What is a “double hit” lymphoma?
• Recurrent breakpoints activating multiple
oncogenes, one being MYC
• BCL2+/MYC+ most common
• BCL6, CCND1 and BCL3 may also occur
• Can also have “triple hit”
6. B cell lymphoma, unclassifiable, with
features intermediate between diffuse
large B cell lymphoma and Burkitt
lymphoma
• WHO 2008 classification
• 35-50% of cases have a MYC
translocation, 15% have a BCL2
translocation
• Increasing incidence with age
• Many are DH
7. Immunophenotype of “double hit”
lymphoma
• CD10+, GCB phenotype
• Lack MUM1/IRF4
• BCL2 + in 95% of cases
• High proliferative index
– median 90% Ki67+
Aukema et al, Blood 2011
8. Clinical features of “double hit” lymphoma
Aukema et al, Blood 2011
Study
N DH/
total N
(%)
DH w
prior
iNHL
%
Med
age
St III/IV
%
LDH >
Nl
%
BM
+ %
CNS +
%
> 1
ENS %
IPI
Hi/HiI
%
Bertrand
2007
10/17
(59%)
10% 58 70% NA NA NA NA 56%
Johnson
2009
54/54
(100%)
46% 62 76% 50% 71% NA 35% 70%
Kanungo
2006
14/14
(100%)
None 55 NA 93% 79% 21% 57% NA
Le Gouill
2007
16/16
(100%)
25% 61 100% 100% 94% 50% 88% 81%
Macpherson
1999
15/39
(38%)
46% 65 92% 80% 69% NA 62% 90%
Niitsu 2009 19/19
(100%)
None 61 100% 100% 84% 21% 63% 89%
Snuderl
2010
20/20
(100%)
15% 64 95% 100% 59% 45% 30% 85%
Tomita 2009 27/27
(100%)
17% 51 96% 93% 65% 9% 65% 87%
9. Treatment and outcome “double hit” lymphoma
Aukema et al, Blood 2011
Study
No. of
DH/tot (%)
Treatment Regimen
Overall
RR %
Median survival, y
Bertrand 2007 10/17 (59%) NA 50% < 1
Johnson 2009 54/54
(100%)
R-CHOP; HDC +/- SCT; CHOP;
P
NA R-CHOP, 1.4; HD,
0.26; CHOP, 0.42
Kanungo
2006
14/14
(100%)
CT-NOS; CT and BMT NA < 1
Le Gouill 2007 16/16
(100%)
R-CHOP; CHOP; HDC+/- SCT
(incl.allo)
75% 0.42
Macpherson
1999
15/39 (38%) CHOP-like; HDC +/- SCT; P NA 0.21
Niitsu
2009
19/19
(100%)
CycloBEAP; CHOP + hi dose
MTX; CHOP; R-CHOP
89% 1.5
Snuderl 2010 20/20
(100%)
R-ICE/SCT; CHOP; R-CHOP;
CODOX-M/IVAC; EPOCH-R
50% 0.38
Tomita
2009
27/27
(100%)
CHOP; CODOX-M/IVAC;
HyperCVAD
26% 0.5
10. CHOP/CHOEP/R-CHOP and MYC rearranged DLBCL
Klapper et al, Leukemia 2008
EFS
OS
Savage et al, Blood 2009
11. BCL-2 and MYC rearranged “double hit”
lymphomas
Johnson et al, Blood 2009
EFS
OS
55 cases (BCCA) out
of 1260
57% C-MYC + at dx
43% at transformation
12. R-CHOP and MYC rearranged DLBCL
Barrans et al, JCO 2010
EFS
OS
35 (14%) with MYC
rearrangements
19 also had t(14;18)
3 also had BCL6
7 “triple hit”
Therefore most
“MYC+” are “double”
or “triple” hit
13. R-CHOP and MYC rearranged DLBCL
Interaction with IPI and age
Barrans et al, JCO 2010
EFS
OS
14. C-MYC in relapsed DLBCL
• BioCoral study – relapsed DLBCL
• Rearrangements noted
– BCL2 31%
– BCL6 18%
– C-MYC 13%
• C-MYC worse PFS and OS
Thieblemont et al, JCO 2011
15. C-MYC and DH/TH DLBCL and
treatment options
• R-CHOP (nothing to date shown to be
better)
• AutoSCT consolidation
– Significant number don’t get to SCT
• Intensive BL type regimens
• R-EPOCH
16. CODOX-M/IVAC and aggressive B cell lymphoma
Mead et al, Blood 2008
EFS
OS
B cell lymphoma,
Ki67 >95%
Mixture of BL
and DLBCL
Low and high
risk by IPI
All 4 DH patients
died within 5 mo
17. DA-R-EPOCH and MYC+ DLBCL
Dunleavy et al, Lugano 2011
EFS
OS
9 MYC+ DLBCL
99 MYC- DLBCL
Similar
risk by IPI
High RR/PFS in
BL
18. Phase II study of dose adjusted R-
EPOCH in previously untreated BL and
c-MYC + DLBCL
• Inclusion criteria
– Burkitt lymphoma or B-cell lymphoma,
unclassifiable, with features intermediate
between Diffuse Large B-cell lymphoma
and Burkitt Lymphoma
– c-MYC + DLBCL
– c-MYC+ plasmablastic lymphoma
NCT01092182
19. Approach to “variant” DLBCL
• GCB vs non-GCB
– R-CHOP is standard
– Various randomized trials underway
• MYC+, DH, TH
– Consider FISH for MYC, BCL2, BCL6
– Less favorable with R-CHOP
– Unclear if other approaches better
– Prospective studies underway
– Analysis needs incorporation in clinical trials
20. Acknowledgment
Clinical Research
Jia Ruan, M.D., Ph.D.
Richard Furman, M.D.
John P. Leonard, M.D.
Peter Martin, M.D.
Maureen Joyce, R.N.
Patricia Glenn, R.N.
Jamie Ketas
Jessica Hansen
Karen Weil
Jennifer O’Loughlin
Rebecca Elstrom
Biostatistician
Ken Chueng, Ph.D. (Columbia)
Madhu Mazumdar, Ph.D. (Cornell)
Translational Core
Maureen Lane, Ph.D. (Cornell)
Maureen Ward
Laboratory Research
Ari Milneck, M.D., Ph.D.(Cornell)
Katherine Hajjar, M.D. (Cornell)
Shahin Rafii, M.D. (Cornell)
Lymphoma Research Foundation
ASCO Foundation (YIA, CDA)
NIH / NHLBI